LRRC15 antibody
- Known as:
- LRRC15 (anti-)
- Catalog number:
- orb101141
- Product Quantity:
- 100 ug
- Category:
- -
- Supplier:
- Biorb
- Gene target:
- LRRC15 antibody
Related genes to: LRRC15 antibody
- Gene:
- LRRC15 NIH gene
- Name:
- leucine rich repeat containing 15
- Previous symbol:
- -
- Synonyms:
- LIB
- Chromosome:
- 3q29
- Locus Type:
- gene with protein product
- Date approved:
- 2003-04-25
- Date modifiied:
- 2015-08-27
Related products to: LRRC15 antibody
Related articles to: LRRC15 antibody
- The 15-leucine-rich repeat containing membrane protein (LRRC15) is a transmembrane protein derived from the leucine-rich repeat (LRR) superfamily that participates in various cell-cell and cell-extracellular matrix interactions, regulating fibrogenesis, vascular invasion, tumorigenesis, and the formation of the innate immune barrier to drive specific antiviral responses. LRRC15, whose expression is reportedly induced by TGF-β and IL-1β stimulation, was recently found to be associated with the development of skeletal diseases, and its presence has been related to the pathophysiological processes of osteoporosis, osteoarthritis and rheumatoid arthritis. Various transmembrane and intracellular signaling transductions are involved in LRRC15-mediated molecular functions, including integrin, NF-κB, Wnt/β-catenin, etc. Additionally, LRRC15 is considered a novel mesenchymal protein and an important biomarker for the occurrence and development of osteosarcoma. Understanding the role of LRRC15 in the bone, joint and tumor microenvironment will facilitate the development of new therapeutic options-particularly LRRC15-based target therapies-for skeletal diseases. - Source: PubMed
Publication date: 2026/07/24
Lin Zi-HaoHu Zhi-ChaoZhang Chang-QingZhu Zhen-ZhongTang Qian - Inflammatory diseases of connective tissues such as periodontitis and rheumatoid arthritis exhibit localized destruction of matrix collagen and loss of tissue function. These diseases are driven by interconnected signaling pathways that determine disease progression and severity. Both periodontitis and rheumatoid arthritis involve the release of extracellular Vimentin (ECV) from stromal and immune cells at diseased sites, but the processes by which ECV binds to cells and promotes inflammatory signaling are not well defined. Recent data point to several putative ECV receptor proteins, one of which is Leucine-Rich Repeat Containing 15, an orphan receptor and cancer-associated fibroblast marker that contributes to inflammation and matrix destruction. Here, we consider the roles of ECV and LRRC15 in connective tissue diseases and discuss how their interactions may promote matrix destruction. We propose that ECV and LRRC15 signal through β1-integrin/FAK, Wnt/β-catenin, and NF-κB to promote cell adhesion, migration and matrix degradation by local fibroblast and immune cell populations. To obtain further insights into ECV-LRRC15 engagement, we used in silico modelling to predict the most likely binding conformation of the ECV-LRRC15 interaction with MEGADOCK. The most probable model suggests that the convex face of the LRRC15 leucine-rich repeat loop binds to two sites on the α-helices of Vimentin rod domains and to one site on Vimentin's N-terminal head domain, potentially signaling through this interface. In this review, we provide an in-depth overview of the functional links between ECV and LRRC15 and discuss their potential roles as drivers of matrix destruction in periodontitis and rheumatoid arthritis. - Source: PubMed
Publication date: 2026/08/07
Yang Claire XNorouzi MasoudAbovsky MarkJurisica IgorMcCulloch Christopher A - Rheumatoid arthritis (RA) and osteoarthritis (OA) frequently coexist, complicating diagnosis and treatment. The extracellular matrix (ECM) serves as a critical modulator of disease progression, coordinating multilayered matrix degradation and inflammatory cascades in both conditions. This study aims to identify ECM-driven molecular signatures to stratify the risk of RA and OA. - Source: PubMed
Publication date: 2026/08/05
Huang BiaojieHuang YuhanLv RuWang WeikaiHu ZhihaoLi GuiboWei ChenChen XiLi ZhengdongZhang Xue - The tumor microenvironment, particularly the tumor stroma, plays a critical role in tumor progression, immune evasion, and therapeutic resistance. However, its interaction with the immune landscape in rectal cancer (RC) remains incompletely understood. This study aimed to comprehensively characterize the stromal-immune ecosystem associated with the tumor stroma ratio (TSR) in RC and to evaluate its clinical and therapeutic relevance. - Source: PubMed
Publication date: 2026/08/03
Wang QianyuTian NaGuo HanchuanXiang YingshiXiao YiLin GuoleZhang GuannanXu LaiLu JunyangChen GangCai HuiyunDu XiaohuiDu JunfengWu Bin - Leucine-rich repeat-containing 15 (LRRC15) is a membrane protein whose overexpression has been linked to poorer survival outcomes in various malignant neoplasms. However, its role in distal extrahepatic bile duct carcinoma (DBDC) remains unclear. LRRC15 protein expression in tumor cells and stroma was evaluated with 196 surgically resected DBDCs, and compared with clinicopathological variables, including patients' overall survival (OS) and recurrence-free survival (RFS). LRRC15 protein expression was identified in stroma of 21 DBDCs (11%) and tumor cells in 67 cases (34%). On the basis of the combined expression patterns of LRRC15, DBDCs were classified into 4 groups: LRRC15 cancer+/stroma- (25%), cancer-/stroma+ (2%), cancer+/stroma+ (9%), and cancer-/stroma- (64%). The stromal LRRC15+ group exhibited more frequent pancreatic invasion compared with the stromal LRRC15- group ( P =0.004*). The LRRC15 cancer+/stroma+ group showed the most frequent pancreas invasion ( P =0.016*). The patients with stromal LRRC15+ group had significantly worse OS (5-year survival rate, 15.4% vs. 31.6%; P =0.013*) and RFS (19.1% vs. 38.9%; P =0.005*) compared with those in the stromal LRRC15- DBDCs. Stromal LRRC15 expression was significantly associated with poor prognosis and showed a strong trend toward being an independent prognostic factor for both OS ( P =0.051) and RFS ( P =0.061). Patients with DBDCs in the LRRC15 cancer+/stroma+ group had the worst RFS ( P =0.010*) and OS ( P =0.008*) by univariate analysis. LRRC15 overexpression was observed in a subset of DBDCs and was associated with pancreatic invasion and worse OS and RFS. Consequently, LRRC15 expression can be used as an indicator of poor survival in patients with DBDCs, particularly when both cancer cells and stromal expression are present. - Source: PubMed
Publication date: 2026/07/15
Chun JihyunJung Deok-BeomShin JinhoJeong HyehyunYoo ChanghoonMyung Seung-JaeHong Seung-Mo